Total amount: € 0,00
Indexed/Abstracted in: BIOSIS Previews, EMBASE, Scopus, Emerging Sources Citation Index
Online ISSN 1827-1812
Elisabetta GARIBALDI 1, Elena DELMASTRO 1, Domenico GABRIELE 2, Monica GARIBALDI 2, Valeria PIRRO 3, Marcello TUCCI 4, Sara BRESCIANI 5, Pietro GABRIELE 1
1 Department of Radiation Oncology, Candiolo Cancer Institute, Candiolo, Turin, Italy; 2 Section of Physiology, Department of Neuroscience, University of Turin, Turin, Italy; 3 Department of Nuclear Medicine, Candiolo Cancer Institute, Candiolo, Turin, Italy; 4 Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Turin, Italy; 5 Department of Medical Physics, Candiolo Cancer Institute, Candiolo, Turin, Italy
We describe the case of an oligo-metastatic prostate cancer patient successfully treated over a period of 11 years, by radiotherapy and systemic therapies. The patient’s clinical history began in 1999 when he was treated by radiotherapy on prostate bed and concurrent maximal androgen blockade (MAB). After an initial biochemical response, in 2004 he had a disease relapse in pelvic nodes and MAB was restarted. Due to persistence of disease in pelvic nodes, Docetaxel was started in February 2007, with a partial response and then in 2008 radiotherapy was performed on the pelvic node (with PSA decreasing <0.1 ng/mL). In April 2011 restaging showed metastasis in left adrenocortical gland and lumbar-aortic nodes: radiotherapy was performed, with good biochemical response. In April 2013 a metastases in a supraclavicular lymph node was found and Docetaxel was re-started, with good biochemical response. In October 2014 patient had a recurrence in the iliac and neck nodes. In December 2014 radiotherapy was performed, on bilateral positive submandibular nodes and left positive supraclavicular node, with concurrent Abiraterone acetate. At last follow-up (December 2015) PSA was 0.001 ng/mL.